IP Library › Granted Patent US 12,410,247
Granted Patent B2
US 12,410,247 · App. 17/647,082 · Granted Sep 9, 2025

Polynucleotides encoding antibodies that specifically bind to human IL-15

Inventors: David Jose Simon Laine (Macquarie Park, AU); Matthew Pollard (Pullenvale, AU); Anthony Gerard Doyle (Macquarie Park, AU); Lynn Dorothy Poulton (Macquarie Park, AU); Adam William Clarke (Macquarie Park, AU)
Assignee: Cephalon LLC
C07K16/244A61P1/00A61P3/00A61P29/02A61P37/00A61K2039/505C07K2317/565C07K2317/76
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,410,247
App. No.
17/647,082
Granted
Sep 9, 2025
Kind
B2
Abstract

Recombinant antibodies that specifically bind to IL-15 as well as a complex of IL-15 and the IL-15 Receptor-alpha are provided. The antibodies inhibit immune cell proliferation, and are capable of use in the treatment of any autoimmune or inflammatory disease or condition where IL-15 is dysregulated, including Celiac disease.

Claims (20)

1. A polynucleotide encoding an antibody, wherein the antibody comprises an HCDR1, an HCDR2 and an HCDR3 comprising the amino acid sequences of SEQ ID NO: 16, 17 and 20, respectively; and an LCDR1, an LCDR2 and an LCDR3 comprising the amino acid sequences of SEQ ID NO:25, 28 and 29, respectively; and wherein the antibody specifically binds to human IL-15 when the IL-15 is complexed with IL-15Ra.

2. The polynucleotide according to claim 1 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 5, a heavy chain constant region comprising the amino acid sequence of SEQ ID NO:49, and an light chain comprising the amino acid sequence of SEQ ID NO:6.

3. A vector comprising the polynucleotide according to claim 1 .

4. A cell transfected with the vector according to claim 3 .

5. A polynucleotide encoding an antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1, or an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO:2.

6. The polynucleotide according to claim 5 , wherein the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 4.

7. The polynucleotide of claim 6 , comprising the nucleic acid sequence of SEQ ID NO: 517.

8. The polynucleotide according to claim 5 , wherein the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO: 5.

9. The polynucleotide of claim 8 , comprising the nucleic acid sequence of SEQ ID NO: 518.

10. A polynucleotide encoding an antibody heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 1, and an antibody light chain variable region comprising the amino acid sequence of SEQ ID NO:2.

11. The polynucleotide according to claim 10 , wherein the antibody heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 4, and the antibody light chain variable region comprises the amino acid sequence of SEQ ID NO:5.

12. An isolated host cell comprising a first polynucleotide comprising a nucleic acid sequence encoding an antibody heavy chain variable region comprising an HCDR1, an HCDR2 and an HCDR3 comprising the amino acid sequences of SEQ ID NO: 16, 17 and 20, respectively; and a second polynucleotide comprising a nucleic acid sequence encoding an antibody light chain variable region comprising an LCDR1, an LCDR2 and an LCDR3 comprising the amino acid sequences of SEQ ID NO:25, 28 and 29, respectively, wherein the antibody specifically binds to human IL-15 when the IL-15 is complexed with IL-15Ra.

13. The isolated host cell of claim 12 , wherein the two polynucleotides are contained in a same vector.

14. The isolated host cell of claim 12 , wherein the two polynucleotides are contained in different vectors.

15. The isolated host cell according to claim 12 , wherein the first polynucleotide encodes an antibody heavy chain comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:5, and a heavy chain constant region comprising the amino acid sequence of SEQ ID NO:4; and wherein the second polynucleotide encodes an antibody light chain comprising the amino acid sequence of SEQ ID NO:6.

16. A transformed cell that comprises one or more expression vectors comprising one or more polynucleotides encoding an antibody, wherein the antibody comprises an HCDR1, an HCDR2 and an HCDR3 comprising the amino acid sequences of SEQ ID NO: 16, 17 and 20, respectively; and an LCDR1, an LCDR2 and an LCDR3 comprising the amino acid sequences of SEQ ID NO:25, 28 and 29, respectively; and wherein the antibody specifically binds to human IL-15 when the IL-15 is complexed with IL-15 Receptor alpha (IL-15Ra).

17. The transformed cell according to claim 16 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:5, a heavy chain constant region comprising the amino acid sequence of SEQ ID NO:49, and a light chain comprising the amino acid sequence of SEQ ID NO:6.

18. The transformed cell according to claim 16 , wherein the cell is a mammalian cell.

19. The transformed cell according to claim 18 , wherein the mammalian cell is a Chinese Hamster Ovary cell.

20. A method of producing an antibody comprising an HCDR1, an HCDR2 and an HCDR3 comprising the amino acid sequences of SEQ ID NO: 16, 17 and 20, respectively; and an LCDR1, an LCDR2 and an LCDR3 comprising the amino acid sequences of SEQ ID NO:25, 28 and 29, respectively, the method comprising culturing the cell of claim 16 to produce the antibody.

Assignments (2)
CHANGE OF NAME Recorded Jun 29, 2023
From: CEPHALON, INC.
To: CEPHALON LLC
Reel/Frame 064176/0907 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2022
From: LAINE, DAVID JOSE SIMON; POLLARD, MATTHEW; DOYLE, ANTHONY GERARD; POULTON, LYNN DOROTHY; CLARKE, ADAM WILLIAM
To: CEPHALON, INC.
Reel/Frame 058581/0007 →
Continuity (3)
Division 16471616
Provisional Application 62437143 · Dec 21, 2016
Related Publication 20220127352A1 · Apr 28, 2022
References Cited (56)
US 6165466A · Grabstein et al. · 2000 [cited by applicant]
US 7083784B2 · Dall'Acqua et al. · 2006 [cited by applicant]
US 7217797B2 · Hinton et al. · 2007 [cited by applicant]
US 7329405B2 · van de Winkel et al. · 2008 [cited by applicant]
US 20030138421A1 · van de Winkel et al. · 2003 [cited by applicant]
US 20030235586A1 · van de Winkel et al. · 2003 [cited by applicant]
US 20040073011A1 · Hagay et al. · 2004 [cited by applicant]
US 20080187531A1 · Babcook et al. · 2008 [cited by applicant]
US 20090053243A1 · Kurosawa et al. · 2009 [cited by applicant]
US 20090068175A1 · Lazar et al. · 2009 [cited by applicant]
US 20090092599A1 · Lazar et al. · 2009 [cited by applicant]
US 20090142340A1 · Lazar et al. · 2009 [cited by applicant]
US 20130078251A1 · Freytag et al. · 2013 [cited by applicant]
US 20130115166A1 · Clark et al. · 2013 [cited by applicant]
US 20130330335A1 · Bremel et al. · 2013 [cited by applicant]
US 20140182003A1 · Bradley et al. · 2014 [cited by applicant]
US 20140248238A1 · Wilson et al. · 2014 [cited by applicant]
US 20140370019A1 · Bruenker et al. · 2014 [cited by applicant]
US 20160145354A1 · Bacac et al. · 2016 [cited by applicant]
US 20200270339A1 · Laine et al. · 2020 [cited by applicant]
CL 2019001001A1 · 2020 [cited by applicant]
EP 2963057A1 · 2016 [cited by applicant]
KR 20050103306A · 2005 [cited by applicant]
WO WO0042072A1 · 2000 [cited by applicant]
WO WO03017935A2 · 2003 [cited by applicant]
WO WO2008151081A1 · 2008 [cited by applicant]
WO WO2009047356A1 · 2009 [cited by applicant]
WO WO16001275A1 · 2016 [cited by applicant]
WO WO2016156440A1 · 2016 [cited by applicant]
WO WO2017217985A1 · 2017 [cited by applicant]
WO WO2018071919A1 · 2018 [cited by applicant]
McInnes et al., Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol. Aug. 2004; 4(4):392-7. [cited by examiner]
Abadie, V., et al., “IL-15: a central regulator of celiac disease immunopathology,” Immunological Reviews 260(1): 221-234, Wiley-Blackwell Publishing Ltd., United Kingdom (Jul. 2014). [cited by applicant]
Baslund, B., et al., “Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study,” Arthritis & Rheumatism 52(9): 2686-2692, W.B. Saunders Ltd., United Kingdom (Sep. 2005). [cited by applicant]
Bethune, M. T., et al., “A non-human primate model for gluten sensitivity,” PLoS One 3(2):e1614, Public Library of Science, United States (Feb. 2008). [cited by applicant]
Biesiekierski, J., and Iven, J., “Non-coeliac gluten sensitivity: piecing the puzzle together,” United European Gastroenterology Journal 3(2): 160-165, SAGE Publications Inc., United States (Apr. 2015). [cited by applicant]
Chen, J., et al., “Increased serum soluble IL-15Rα levels in T-cell large granular lymphocyte leukemia,” Blood 119(1): 137-143, American Society of Hematology, United States (Jan. 2012). [cited by applicant]
Finch, D. K., et al., “Identification of a potent anti-IL-15 antibody with opposing mechanisms of action in vitro and in vivo,” British Journal of Pharmacology 162(2): 480-490, Wiley-Blackwell, United States (Jan. 2011). [cited by applicant]
Labrijn, A. F., et al., “Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo,” Nature Biotechnology 27(8): 767-773, Nature Publishing Group, United Kingdom (Aug. 2009). [cited by applicant]
Lebrec, H., et al., “Homeostasis of human NK cells is not IL-15 dependent,” The Journal of Immunology 191(11): 5551-5558, American Association of Immunologists, United States (Dec. 2013). [cited by applicant]
Padlan, E. A., et al., “Identification of specificity-determining residues in antibodies,” The FASEB Journal 9(1): 133-139, Federation of American Societies for Experimental Biology, United States (Jan. 1995). [cited by applicant]
Rishi, A. R., et al., “Refractory celiac disease,” Expert Review of Gastroenterology & Hepatology 10(4): 537-546, Taylor and Francis Ltd., United Kingdom (published online Dec. 2015; 2016). [cited by applicant]
Shrake, A., and Rupley, J. A., “Environment and exposure to solvent of protein atoms. Lysozyme and insulin,” Journal of Molecular Biology 799(2): 351-371, Elsevier, Netherlands (Sep. 1973). [cited by applicant]
Sestak, K., et al., “Supplementation of Reduced Gluten Barley Diet with Oral Prolyl Endopeptidase Effectively Abrogates Enteropathy-Associated Changes in Gluten-Sensitive Macaques,” Nutrients 8(7): 401, MDPI Multidiscip… [cited by applicant]
UniProtKB—P01857 (IGHG1_Human), “Immunoglobulin heavy constant gamma 1,” Accession No. P01857, accessed at https://www.uniprot.org/uniprot/P01857, accessed on May 5, 2020, 2 pages. [cited by applicant]
Villadsen, L. S., et al., “Resolution of psoriasis upon blockade of IL-15 biological activity in a xenograft mouse model,” The Journal of Clinical Investigation 112(10): 1571-1580, The American Society for Clinical Inve… [cited by applicant]
Waldmann, T. A., et al., “Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases,” Arthritis Research & Therapy 6(4): 174-177, BioMed Central Ltd., United Kingdom (Jun. 2004). [cited by applicant]
Bernard, J., et al., “Identification of Interleukin-15 Receptor-binding Site on Human Interleukin-15,” Journal of Biological Chemistry 279(23):417-433, American Society for Biochemistry, United States (Jun. 2004). [cited by applicant]
International Search Report and Written Opinion in international application No. PCT/US2017/067917, mailed May 8, 2018, ISA/US, Commissioner for Patents, Alexandria, Virginia, United States, 18 pages. [cited by applicant]
Thaysen-Andersen, M., et al., “Recombinant human heterodimeric IL-15 complex displays extensive and reproducible N- and O-linked glycosylation,” Glycoconjugate Journal 33(3):417-433, Springer Science+Business Media, Ger… [cited by applicant]
Vicari, A. P., et al., “Discovery and characterization of a novel humanized anti-IL-15 antibody and its relevance for the treatment of refractory celiac disease and eosinophilic esophagitis,” Monoclonal Antibodies 9(6):… [cited by applicant]
Edelman, G. M., et al., “The Covalent Structure of an Entire gammaG Immunoglobulin Molecule,” Proc Natl Acad Sci USA 63(1):78-85, National Academy of Sciences, United States (May 1969). [cited by applicant]
Ku, J., and Schultz, P. G., “Alternate protein frameworks for molecular recognition,” Proc Natl Acad Sci USA 92(14):6552-6556, National Academy of Sciences, United States (Jul. 1995). [cited by applicant]
Gorski, K., et al., “The Fully Human Anti-IL-15 Antibody AMG 714, in Development for Celiac and Refractory Celiac Disease, Does not Reduce Circulating Numbers of Human Natural Killer Cells or Preclude Their in Vitro Act… [cited by applicant]
Sestak, K., et al., “Beneficial Effects of Human Anti-Interleukin-15 Antibody in Gluten-Sensitive Rhesus Macaques with Celiac Disease,” Frontiers in Immunology 9:1603, Frontiers Media S.A., Switzerland (Jul. 2018). [cited by applicant]
Waldmann, T. A., “The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders,” J Investig Dermatol Symp Proc 16(1):S28-30, Nature Publishing Group for the Society for Investigative D… [cited by applicant]